Compare Gilead Sciences, Inc. (GILD) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Gilead Sciences, Inc. trades at $136.32 (market cap $168.35B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $244.13 (market cap $46.84B). The key difference: Gilead Sciences, Inc. is far larger — about 3.6× TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock pays none. Which is the better fit depends on your goals.
| GILD | TTWO | |
|---|---|---|
Market Cap | $168.35B | $46.84B |
Sector | Health | Media |
52-Week High | $155.80 | $262.29 |
52-Week Low | $110.56 | $189.69 |
Enterprise Value | $191.42B | $47.96B |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $135.78, up 2.04% on the day, with a bullish technical signal and strong support at $134. Recent Q2 2026 earnings beat revenue estimates despite a net loss, driven by 10% base business growth from HIV drugs like Biktarvy. The company raised its full-year sales outlook, but faces a negative net income margin of -10.64% and elevated debt levels.
The outlook is mixed: robust HIV franchise growth and a 67% analyst buy rating support upside to the $151.22 consensus target, but acquisition costs, patent cliff risks, and volatile cash flows pose challenges. Investment appeal hinges on pipeline execution offsetting margin pressure.
Take-Two Interactive (TTWO) trades at $243.60, down 3.93% over 24 hours, with a bullish technical signal from moving averages and support near $240. The company reported Q1 2026 EPS of $0.80, beating estimates, but faces fundamental challenges with a net income margin of -4.79% and negative ROE of -9.04%. Recent news highlights strong GTA VI pre-orders as a key catalyst, with FY2027 net bookings guidance maintained at $8-$8.2 billion (company earnings report, August 7, 2026).
Outlook is optimistic due to GTA VI's November 2026 launch potential, but risks include high debt levels (debt-to-asset ratio of 39.87% in 2025) and consistent net losses. Analyst consensus is strongly bullish with a $300.55 price target, suggesting 23% upside from current levels if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
